Detalles de la búsqueda
1.
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Lancet
; 384(9961): 2213-27, 2014 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25189358
2.
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Hum Vaccin
; 7(12): 1343-58, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048173
3.
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study.
Pediatr Infect Dis J
; 30(3): e49-55, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21273939
Resultados
1 -
3
de 3
1
Próxima >
>>